Part B Placebo

BIOLOGICAL3 trials

Sponsors

Stealth BioTherapeutics Inc., DBV Technologies, MedImmune LLC

Conditions

AtherosclerosisCardiovascular DiseaseFuchs' Corneal Endothelial Dystrophy (FCED)Peanut Allergy

Phase 1

A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

CompletedNCT02653391

Stealth BioTherapeutics Inc.Fuchs' Corneal Endothelial Dystrophy (FCED)

Start: 2016-02-29End: 2018-12-31Updated: 2021-09-17

Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus

CompletedNCT03654313

MedImmune LLCAtherosclerosis, Cardiovascular Disease

Start: 2018-09-28End: 2020-07-21Updated: 2020-08-24

Phase 3

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

CompletedNCT03211247

DBV TechnologiesPeanut Allergy

Start: 2017-07-31End: 2022-04-27Updated: 2024-12-16

Related Papers

Efficacy and safety of epicutaneous immunotherapy in children with peanut allergy with atopic comorbidities

Annals of Allergy Asthma & Immunology2025-04-081 citations

Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy

New England Journal of Medicine2023-05-10115 citations

Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results

Journal of the American Heart Association2023-01-2318 citations

Abstract 11971: Identification of Response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes

Circulation2022-11-082 citations